Revenue
2022
2023
2024
2025
Atara Biotherapeutics, Inc. (ATRA)
Price$9.76Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $128.9M | $8.6M | $63.6M | — | — | — | — | — | — | — | — | — |
| Research & development | $37.4M | $151.5M | $224.8M | $272.5M | $282.0M | $244.7M | $216.1M | $167.5M | $81.2M | $56.5M | $41.6M | $14.4M | $4.3M |
| Operating expenses | $84.9M | $212.4M | $284.6M | $344.1M | $360.8M | $309.1M | $295.7M | $237.1M | $121.5M | $81.2M | $58.4M | $28.2M | $8.6M |
| Operating income | $35.9M | −$83.4M | −$276.0M | −$280.5M | −$340.5M | −$309.1M | −$295.7M | −$237.1M | −$121.5M | −$81.2M | −$58.4M | −$28.2M | −$8.6M |
| Operating margin | 29.69% | −64.71% | −3,219.48% | −441.25% | — | — | — | — | — | — | — | — | — |
| EBITDA | $38.0M | −$78.4M | −$271.2M | −$274.9M | −$331.1M | −$300.7M | −$288.6M | −$233.4M | −$120.6M | −$80.9M | −$58.4M | −$28.1M | −$8.6M |
| EBITDA margin | 31.45% | −60.79% | −3,163.15% | −432.35% | — | — | — | — | — | — | — | — | — |
| Net income | $32.7M | −$85.4M | −$276.1M | −$228.3M | −$340.1M | −$306.6M | −$291.0M | −$230.7M | −$119.5M | −$79.0M | −$57.2M | −$28.0M | −$8.8M |
| Net profit margin | 27.07% | −66.23% | −3,220.88% | −359.12% | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | $2.61 | -$11.41 | -$65.19 | -$56.00 | -$90.75 | -$103.75 | -$141.75 | -$131.75 | -$100.00 | -$68.75 | — | — | — |
| Diluted EPSper diluted share | $2.57 | -$11.41 | -$65.19 | -$56.00 | -$90.75 | -$103.75 | -$141.75 | -$131.75 | -$100.00 | -$68.75 | — | — | — |
Owners
Reported shareholders
16.44%of listed shares
EcoR1 Capital, LLC1.55M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
EcoR1 Capital, LLC | 16.44%1.55M shares |
Panacea Innovation Ltd / Huang James | ≈13.97%1.32M shares |
Ciongoli Gregory Austin | ≈12.93%1.22M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 9.00%850K shares |
Point72 Asset Management, L.P. | 7.28%687.72K shares |
Redmile Group, LLC | 4.68%441.7K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.62%247.05K shares |
MACKENZIE FINANCIAL CORP | 2.47%233.25K shares |
Nguyen AnhCo | ≈1.46%137.84K shares |
BlackRock, Inc. | 0.89%84.46K shares |
Touchon Pascal | ≈0.83%77.96K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.80%75.13K shares |
Cherry Brian N | ≈0.66%62.32K shares |
Hyllengren Eric J | ≈0.60%56.23K shares |
STALEY CAPITAL ADVISERS INC | 0.53%50K shares |
Grant-Huerta Yanina | ≈0.53%49.64K shares |
VANGUARD FIDUCIARY TRUST CO | 0.46%43.04K shares |
ACADIAN ASSET MANAGEMENT LLC | 0.41%38.85K shares |
HEIDEN WILLIAM K | ≈0.36%34.19K shares |
Gallagher Carol Giltner | —33.01K shares |
Percentages use 9.44M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | Nguyen AnhCoPresident and CEO | SellCommon Stock | 5.2K | $9.13 | $47.9K | 137.8K |
| May 18, 2026Form 4 | Grant-Huerta YaninaChief Accounting Officer | SellCommon Stock | 2.4K | $9.13 | $22.0K | 49.6K |
| May 7, 2026Form 4 | Panacea Innovation Ltd +1TenPercentOwner | SellCommon Stock · indirect | 313.4K | $10.10 | $3.17M | 1.01M |
| May 7, 2026Form 4 | EcoR1 Capital, LLCTenPercentOwner | BuyCommon Stock · indirect | 507.4K | $9.35 | $4.74M | 1.55M |
| Mar 2, 2026Form 4 | Grant-Huerta YaninaChief Accounting Officer | SellCommon Stock | 100 | $5.08 | $508.00 | 31.8K |